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a  b  s  t  r  a  c  t
Aim:  Besides  supportive  care, the  only  recommended  treatment  for  comatose  patients  after  cardiac  arrest
is  target  temperature  management.  Helium  reduces  ischaemic  injury  in  animal  models,  and  might  ame-
liorate neurological  injury  in patients  after  cardiac  arrest.  As no  studies  exist  on  the  use  of  helium  in
patients  after  cardiac  arrest  we  investigated  whether  this  is  safe  and  feasible.
Methods:  The  study  was  an  open-label  single  arm  intervention  study  in a  mixed-bed  academic  intensive
care  unit.  We  included  25  patients  admitted  after  circulatory  arrest,  with  a  presenting  rhythm  of  ven-
tricular  ﬁbrillation  or pulseless  tachycardia,  return  of spontaneous  circulation  within  30  min  and  who
were  treated  with  hypothermia.  Helium  was  administrated  in  a 1:1 mix  with  oxygen  for  3 h.  A safety
committee  reviewed  all  ventilation  problems,  complications  and causes  of  mortality.
Results:  Helium  ventilation  was  started  4:59  ± 0:52  (mean  ±  SD)  h after  circulatory  arrest.  In one  patient,
helium  ventilation  was  discontinued  prematurely  due  to  oxygenation  problems.  This  was  caused  by pre-
existing  pulmonary  oedema,  and  imposed  limitations  to PEEP  and  FiO2 by  the  study  protocol,  rather  than
the  use  of helium  ventilation.  Sixteen  (64%)  patients  had  a favourable  neurological  outcome.
Conclusions:  We  found  that helium  ventilation  is  feasible  and can be used  safely  in patients  treated  with
hypothermia  after  cardiac  arrest.  No  adverse  events  related  to the  use of  helium  occurred  during  the
three hours  of  administration.
©  2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC  BYntroduction
Out of hospital cardiac arrest (OHCA) is a major cause of mor-
idity and mortality, afﬂicting 335 per million per year in the
etherlands with an overall mortality of 81%.1 Half of the patients
dmitted to the intensive care unit (ICU) leave the hospital with an
 A Spanish translated version of the abstract of this article appears as Appendix
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unfavourable outcome.2,3 Circulatory arrest and subsequent return
of circulation leads to ischaemia reperfusion injury of the whole
body and is particularly injurious to the brain and myocardium.4,5
Brain injury is the major cause of mortality and morbidity after
cardiac arrest.6 Therefore, patients admitted after cardiac arrest
should receive treatment aimed at reducing brain injury as part of
the post-resuscitation care. The only effective treatment currently
available is target temperature management.7–10 Despite this ther-
apy, outcome results are disappointing and therapies to further
reduce ischaemia reperfusion injury after OHCA are needed.
Helium reduces ischaemia reperfusion injury to the heart and
the brain in animal models, suggesting that helium might be capa-
ble of reducing neurological and myocardial injury in patients after
OHCA.11–17 However no clinical studies in this ﬁeld have been done
yet. Recently we demonstrated that helium induces precondition-
ing in healthy volunteers, thereby protecting against endothelial
s article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).




























































Male sex 20 (80%)
Age (years) 64.8 ± 12.1
BMIa (kg/m2) 27.4 ± 4.8
SAPS II scoreb 53.6 ± 18.6
APACHE II scorec 20.0 ± 8.6
Comorbidity cardiovascular disease 14 (56%)
Malignancy 4 (16%)
Cause of OHCAd Acute infarction 17 (68%)
Chronic infarction 4 (16%)
Structural heart disease 3 (12%)
Unknown 1 (4%)
Time to 1st shock (min) 8 ± 7
Time to ROSCe (min) 16 ± 7
CAGf, 20 (80%)
PCIg 15 (60%)
IABPh or impella 9 (36%)
Inotropics or vasopressors 12 (48%)
a Body Mass Index.
b Simpliﬁed acute physiology score II.
c Acute physiology and chronic health evaluation II.
d Out-of-hospital cardiac arrest.
e Return of spontaneous circulation.
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ysfunction after regional forearm ischaemia.18 Clinically, helium
s used to ventilate both adults and children with severe obstructive
ulmonary disease and helium inhalation is generally considered
o be safe.19 Prior to investigating the use of helium as a therapeu-
ic agent in neurological damaged patients, we performed a safety
nd feasibility study, investigating whether helium ventilation can
afely be used in patients admitted to the ICU after OHCA.
ethods
This was an open-label single arm intervention study, per-
ormed in the mixed surgical and medical ICU of the Academic
edical Centre, Amsterdam, the Netherlands. The study was
pproved by the medical ethics committee of the Academic Medi-
al Centre (protocol number NL 30466.018.09) and was conducted
n concordance with the principles of the declaration of Helsinki
nd good clinical practice. Patients were included after obtaining
nformed consent from their legal representative.
Inclusion criteria were admissioned after witnessed OHCA, with
he ﬁrst registered rhythm being ventricular ﬁbrillation (VF) or
achycardia (VT) and treatment with mild hypothermia (target
emperature 33 ◦C). Return of spontaneous circulation (ROSC) had
o occur within 30 min  and helium ventilation had to be started
ithin 6 h after cardiac arrest. Exclusion criteria were oxygenation
roblems (necessitating a FiO2 > 50% and >10 cmH2O positive end
xpiratory pressure [PEEP]), neurological deﬁcits or severe disabil-
ty before cardiac arrest, comorbidities with a life expectancy of less
han 6 months and pregnancy. The described ventilation settings
ere limits during the study-protocol as well.
tudy procedures
After inclusion, helium ventilation was initiated as soon as pos-
ible. Helium was administered using a heliox compatible Servo-I
entilator (Maquet, Netherlands), which was calibrated to accu-
ately measure tidal volumes when using heliox. Helium was
upplied from a pressurised cylinder containing 1780 L heliox
Heliox21, BOC Ltd., UK), as a 79/21 helium/oxygen mixture, and
as mixed in the ventilator with oxygen to obtain an ﬁnal gas mix
f 50% helium and 50% oxygen. Helium ventilation was done in
ressure control mode, which was the standard ventilation mode in
ur ICU, peak pressure was set to achieve a tidal volume of 6 ml/kg
deal body weight, with 5–10 cmH2O of PEEP and the respiratory
requency was controlled to maintain a pCO2 of 4.5–5.5 kPa and a
H of 7.35–7.45 (alpha-stat). A pO2 of ≥10 kPa and a saturation of
95% were aimed for. After switching to helium, a setup period with
epeated blood gas analyses was used to reach the target values for
CO2 and pH. When these measurements were within the target
alues helium ventilation was continued for a 3-h period. Since the
bjective of this study was  to investigate the safety and feasibil-
ty, and not the effectiveness, helium ventilation was stopped if the
ylinder was empty before the end of the 3-h period.
Data collected were age, gender, Body Mass Index (BMI), simpli-
ed acute physiology score II (SAPS II), acute physiology and chronic
ealth evaluation score II (APACHE II), pre-existent cardiovascu-
ar disease or malignancy, cause of arrest, time until ﬁrst shock,
ime to ROSC, the use of coronary angiography and percutaneous
oronary interventions and the need for haemodynamic support at
dmission.
Serum samples for analysis of creatine kinase (CK), creatine
inase muscle-brain (CK-MB) and troponin-T were drawn at admis-
ion and at 6, 12, 18, 24, and 48 h. Serum samples for analysis
f neuro speciﬁc enolase (NSE) levels were drawn 24 and 48 h
fter admission. NSE serum samples were centrifuged and stored
t −80 ◦C until analysis by immunoassay (kit for ELECSYS, Roche).Coronary angiography.
g Percutaneous coronary intervention.
h Intra-aortic balloon pump.
Outcome was assessed by telephone interview of the patient
or caregiver 30 days after admission. The Glasgow Outcome Scale
(GOS) was used; poor outcome was  deﬁned as death or vegetative
state (GOS 1-2).20 Primary objective of the study was to investigate
the safety and feasibility of helium administration in patients after
cardiac arrest. Safety endpoints were the inability to adequately
ventilate the patient using helium within the predetermined lim-
its (FiO2 50% and ≤10 cmH2O PEEP), and death related to helium.
To determine the probability of an adverse event being related to
helium treatment all serious adverse events were evaluated by an
independent safety committee, consisting of an independent inten-
sive care physician, anaesthesiologist and neurologist.
Secondary objectives were to investigate the effect of helium
ventilation on outcome (GOS), brain injury (NSE) and cardiac injury
(CK, CK-MB, and troponin-T).
Statistics
There is no data on the effectiveness or the occurrence of adverse
events of helium treatment in patients after OHCA. Therefore, a for-
mal  sample size calculation could not be performed. We expected a
mortality rate of approximately 50%, and therefore chose to include
25 patients, to be able to detect an increase in adverse events
related to helium. This is also a sample size that is used in similar
studies.21,22
SPSS 19 (IBM, Armonk, New York, USA) was  used for statistical
analysis unless stated otherwise. Continuous data are presented
as mean with standard deviation when normally distributed, and
otherwise as median and interquartile range, while categorical data
are presented as numbers with proportions.
ResultsBetween April 2010 and October 2011, 106 patients admitted
after OHCA were screened for eligibility, of which 64 patients were
not eligible, 13 patients were eligible but were missed by the physi-
cian on call, in four patients study participation was refused by the
D. Brevoord et al. / Resuscitation 107 (2016) 145–149 147




- 9 in-hospital cardiac arr est
- 13 oxygenation problems
- 12  no VF/VT
- 7 ROSC >30 min
- 6 neurological disorder
- 2 no TTM
- 6 participan ts in competing trial 
- 2 pregnancy
- 3 >6 hou rs after arr est
Eli gible but no t included: 21
- 10  missed
- 4 no relatives to obtain con sent
- 2 no heli um availab le
- 1 no resea rche r availab le































vFig. 1. Flow sc
egal representative, and ﬁnally 25 patients were included (Fig. 1).
aseline characteristics of patients are presented in Table 1.
Helium ventilation was started 4:59 ± 0:52 (mean ± SD) h after
rrest, and 21 ± 13 (mean ± SD) min  was used to reach stable
entilator settings with pCO2 and pH within target range. After
hat, helium ventilation was continued for a total of 3:10 ± 0:39
mean ± SD) h. One patient was ventilated longer than the planned
-h period. The effect of helium ventilation on blood gas val-
es and respiratory settings is described in detail elsewhere.23
n six patients the treatment was stopped prematurely; in ﬁve
atients the heliox cylinder was empty before completion of the
-h treatment protocol, due to high minute volumes needed and
he duration of the adjustment period. In one patient, ventilation
ith helium was terminated prematurely. This patient had slight
ypoxia at the time of inclusion due to pulmonary oedema follow-
ng cardiac arrest, requiring 10 cmH2O PEEP and a FiO2 of 50% to
aintain an oxygen saturation (sO2) of >90% and a PaO2 of 8.4 kPa.
hortly after the initiation of helium ventilation, the sO2 dropped
o 84% and the PaO2 to 7.1 kPa, thereby meeting a safety endpoint,
nd it was decided to discontinue the study protocol and switch
ack to a normal gas mixture. Only after increasing FiO2 to 70% and
EEP to 12, oxygenation improved in this patient. These ventila-
ion settings had to be maintained for several days. As the hypoxia
as pre-existing and persisting, the safety committee concluded
hat the ventilation disorders were not caused by the short use of
elium. Although helium treatment was stopped for safety reasons,
his was probably due to the restrictions the study protocol posed
n the settings of PEEP and FiO2, rather than the use of helium itself.
Nine patients died within 30 days (36%); in all patients post-
noxic brain injury was the cause of death. None of these deaths
ere related to helium ventilation. At 30 days follow-up, the sur-
iving 16 patients (64%) all had a favourable outcome, 13 patientsle of patients.
(81%) resided at home, two patients (13%) in a rehabilitation centre
and one patient was  still hospitalized (6%).
Helium treated patients had a mean NSE value of 44 ± 51 g l−1
at 24 h, and 54 ± 94 g l−1 at 48 h after arrest.
Discussion
This is the ﬁrst study focusing on of the use of helium as a
treatment for post cardiac arrest syndrome. We  found that helium
ventilation is feasible and can be used safely in patients treated with
hypothermia after OHCA. No adverse events related to the helium
ventilation occurred during the three hours of ventilation with this
noble gas.
These results might open the door to a new treatment of brain
injury following cardiac arrest. Helium might reduce the reperfu-
sion injury, but our study was not designed to demonstrate this and
subsequent studies on the potential therapeutic value of helium
in organ protection following ischaemia reperfusion are needed.
Although the mortality rate is lower than values normally reported
in the literature for ICU patients admitted after cardiac arrest, this is
probably due to the patient selection.3,24 We included only patients
who had a witnessed arrest, presented with VF or VT, and had a
resuscitation time of thirty minutes or less, all factors that have a
positive effect on outcome.
Comparison of our results to studies with helium or other
noble gasses in patients after cardiac arrest is not possible, as this
has never before been studied. Only animal studies have been
performed showing conﬂicting results regarding neuroprotective
properties of helium. In an in vitro model of traumatic brain injury,
Coburn et al. found a protective effect of helium, and Pan et al.
found a reduction in infarct size by helium inhalation in an in vivo
rat model using MCA  occlusion.12,13 More positive effects in a MCA
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ffect was only seen when the animals were allowed to cool down
n a ﬂow chamber.16 The authors suggested that the protection
as mediated by the induction of hypothermia. Finally, in neonatal
ats in which one common carotid artery was temporally occluded,
iu et al. demonstrated neuroprotection by helium, and Zhuang
t al. conﬁrmed this protection for ischaemia of 90 min, but not for
20 min.17,25 Other studies did not ﬁnd a beneﬁcial effect of helium
n cerebral injury. In an in vitro model using oxygen glucose depri-
ation to induce brain injury, Jawad et al. did not ﬁnd any beneﬁcial
ffect.26 Pan et al. used a model of MCA  occlusion and reported that
elium only provided protection when given directly at the time of
eperfusion, and in an inspired fraction of 70%.27 Until today, the
xact underlying mechanisms mediating possible organ protective
ffects of helium are unclear.28
Other noble gasses are also being investigated as neuropro-
ective agents. In a pig model of cardiac arrest, xenon was  given
fter resuscitation and reduced brain injury.29 The use of xenon in
atients after cardiac arrest seems feasible and safe, although a spe-
ially designed ventilator is required.30 A subsequent randomised
ontrolled trial of 110 patients was published very recently and
ound a reduction in white matter injury on MRI, but no improve-
ent in survival or neurological outcome.31 Xenon is also under
nvestigation as a treatment for neonatal encephalopathy, but a ﬁrst
andomized controlled trial found no beneﬁt on neurological injury
n these patients.32 Helium is less scarce than xenon and cheaper,
nd while xenon requires purposely-designed ventilators, helium
an be administered using common ICU ventilators. If helium ven-
ilation is an effective neuroprotective strategy in patients after
HCA, the application in daily clinical care in the ICU will be much
asier than xenon ventilation.
It is known that the results of animal studies investigating neu-
oprotection in different animal models are difﬁcult to translate to
he human situation. Many neuroprotective drugs have been stud-
ed in stroke patients, based on positive animal experiments, but
o effective drug has ever been found for humans.33,34 A large dif-
erence with focal ischaemic stroke models is that in patients after
HCA the vasculature of the brain is intact and open. As soon as
irculation is restored, neuroprotective agents can easily reach the
rain cells and perform their actions.
We  chose to start with a small study, which makes conclusions
bout possible effectiveness insigniﬁcant and might underestimate
he side effects of helium ventilation. Especially longer periods of
elium ventilation, which might be needed for an optimal treat-
ent effect, could lead to more problems. This would be the logical
opic to address in a subsequent study.
Second, the open-label use of helium inadvertently introduces a
isk for bias, however by using endpoints that are not inﬂuenced by
bserver interpretation (mortality, vegetative state and laboratory
ssessments) the risk for observer bias was reduced.
Third, the setting of a single ICU of a university hospital limits
xtrapolation of the results. However, since the objective of the
tudy was to investigate the safety and feasibility, we feel that these
imitations are of minor concern at this stage.
All patients were ventilated with 50% helium in order to give
he same dosage. This also meant that all patients received 50%
xygen, regardless of their oxygenation status, which could lead to
upernormal oxygen tensions in some patients. A high PaO2 during
r after cardiac arrest has been linked to an increase in mortality,
nd might inﬂuence a beneﬁcial effect of helium.35–37
Prior to further clinical trials, subsequent research should
nclude a relevant animal study, such as a porcine model of car-
iac arrest, to strengthen the data on the efﬁcacy of helium, and to
nswer questions on the required inspiration fraction, the optimal
uration of treatment and the effect of delay between arrest and
he start of helium treatment.
1on 107 (2016) 145–149
Conclusions
We  demonstrated for the ﬁrst time that helium ventilation for
three hours is safe and feasible in patients after OHCA. This might
open the route for further studies investigating the effectiveness of
this new organ protective treatment modality.
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